Positive Choice: Prevention for Positive Health

Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Completed
CT.gov ID
NCT00447707
Collaborator
(none)
497
5
33
99.4
3

Study Details

Study Description

Brief Summary

This is a randomized, controlled trial of Positive Choice, an interactive multimedia computer program, to determine whether it can detect and reduce risky behaviors among HIV-positive adults. The behaviors of interest are: unprotected anal or vaginal intercourse, illicit drug use, risky alcohol drinking, and failure to disclose HIV status to sex partners. The Positive Choice program is integrated into the routine operations of outpatient HIV clinics, where participating patients complete an in-depth risk assessment (computerized health questionnaire) before a regularly scheduled medical appointment. Participants assigned to the intervention arm receive brief, interactive risk-reduction counseling by an actor-portrayed Video Doctor and an educational worksheet. Their health care provider receives as summary cueing sheet, alerting them to the patient's risky behavior and readiness to change. Control participants complete the computerized risk assessment and receive the clinic's usual care. Three months after a baseline visit, intervention and control group patients are invited back to complete an additional risk assessment. The intervention group also receives a "booster" intervention. Six months after baseline, both groups complete a final risk assessment.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Positive Choice
N/A

Detailed Description

A preliminary analysis of baseline data was conducted in January 2006, which indicated that the Positive Choice intervention achieved significant reductions in drug use. These findings were reported in a poster presentation at the XVI International AIDS Conference in Toronto, Canada, in August 2006. A final analysis of outcomes data was conducted in fall 2006 (September - December). Aggregate results from all five study sites are summarized below.

We found a high prevalence of risky behaviors in our sample (497/918, or 54%) and achieved high retention for follow-up in both groups (>80%). We found significant elimination of any drug use in the intervention group at both follow-ups. Among all participants who reported drug use at baseline, 66% of intervention participants continued their drug use at 3-month follow-up compared to 85% of control participants (OR 0.356, p<0.01). At 6-month follow-up, 59% of intervention participants continued their drug use compared to 88% of the control group (<0.001). Among participants who reported methamphetamine use at baseline, 58% continued their methamphetamine use at 3-month follow-up compared to 83% of control participants (OR 0.285, p=0.02). At 6-month follow-up, 53% of intervention participants continued their methamphetamine use compared to 73% of the control group (OR 0.344, p=0.03). We also found significantly less unprotected sex with casual partners by intervention participants at 3-month follow up (69% vs. 87%, OR 0.313, p=0.04), and fewer intervention participants who exceeded the recommended number of drinks per week at 3-months (53% vs. 78%, OR 0.310, p=0.02) Our findings indicate that the Positive Choice program was effective at reducing important behavioral risks among HIV-positive adults in care. Positive Choice is an appropriate and effective adjunct to routine medical care for HIV-positive adults.

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single
Official Title:
Positive Choice: Prevention for Positive Health
Study Start Date :
Dec 1, 2003
Study Completion Date :
Sep 1, 2006

Outcome Measures

Primary Outcome Measures

  1. Elimination of risky drinking, illicit alcohol use, unprotected sex, and non-disclosure of HIV status to sex partners. []

Secondary Outcome Measures

  1. Measures of change in risky alcohol use, illicit drug use, unprotected sex, and non-disclosure of HIV status to sex partners. []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18 years or older,

  • HIV-positive 3 months or longer,

  • English speaking; and

  • Receiving medical care at a participating clinic.

Exclusion Criteria:
  • Less than 18 years old,

  • HIV-positive less than 3 months,

  • Non-English speaking; and

  • Not receiving medical care at a participating clinic.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Adult Immunology Clinic, Highland Hospital Oakland California United States 94602
2 AIDS Project East Bay (APEB) Oakland California United States 94607
3 East Bay AIDS Center (EBAC), Alta Bates Hospital Oakland California United States 94609
4 Kaiser Permanente Medical Center San Francisco California United States 94115
5 Adult Immunology Clinic, Fairmont Hospital San Leandro California United States 94578

Sponsors and Collaborators

  • National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Barbara Gerbert, PhD, University of California, San Francisco

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00447707
Other Study ID Numbers:
  • R01DA015016
First Posted:
Mar 15, 2007
Last Update Posted:
Jan 12, 2017
Last Verified:
Mar 1, 2007

Study Results

No Results Posted as of Jan 12, 2017